<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728091</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10102</org_study_id>
    <secondary_id>EudraCT:2007-007941-10</secondary_id>
    <nct_id>NCT00728091</nct_id>
  </id_info>
  <brief_title>A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia</brief_title>
  <acronym>AQUARIST1</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of satavaptan versus placebo in
      participants with dilutional hyponatremia due to SIADH.

      Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and
      the clinical benefit in these participants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum sodium change from baseline</measure>
    <time_frame>At Day 5 pre-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>responder rate</measure>
    <time_frame>At Day 5 pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence and intensity of clinical symptoms related to hyponatremia</measure>
    <time_frame>At each scheduled visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in cognitive function</measure>
    <time_frame>At Day 5 and 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Inappropriate ADH Syndrome</condition>
  <arm_group>
    <arm_group_label>Satavaptan Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Low dose up to day 4, followed by optional titration up to day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Satavaptan Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed High dose up to day 4, followed by optional titration up to day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satavaptan</intervention_name>
    <description>tablets</description>
    <arm_group_label>Satavaptan Dose 1</arm_group_label>
    <arm_group_label>Satavaptan Dose 2</arm_group_label>
    <other_name>SR121463</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with symptomatic syndrome of inappropriate antidiuretic hormone secretion
             (SIADH) with chronic hyponatremia

        Exclusion Criteria:

          -  Presence of clinical signs of hypovolemia (e.g. orthostatic decreases in blood
             pressure and increase in pulse rate, dry mucus membranes, decreased skin turgor)

          -  Presence of clinical signs of hypervolemia (e.g. generalized edema, jugular venous
             extension)

          -  Participants with adrenocortical insufficiency

          -  Participants with hypothyroidism

          -  Participants with known causes of transient SIADH

          -  Participants with psychogenic polydipsia or beer potomania

          -  Concomitant use of thiazide diuretics during the study

          -  Presence of uncontrolled diabetes with fasting blood glucose ≥200 mg/dL (≥11.09
             mmol/L) at time of screening

          -  Participants with impaired hepatic function or liver cirrhosis (Child-Pugh A-C)

          -  Pregnant or breast-feeding women

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <disposition_first_submitted>April 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 26, 2016</disposition_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aquaretic</keyword>
  <keyword>SIADH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Inappropriate ADH Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Satavaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

